CASI earnings call for the period ending December 31, 2019.
News & Analysis: CASI Pharmaceuticals
Investors are pleased with a plan to sell generic Viread in China.
But it didn't last long.
Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?
With trade tensions heating up between the U.S. and China, here are some things to think about when it comes to the stock market.
The tiny biopharma announced progress for a drug application in China.
Stellar, or stinkers? The CAPS community sounds off.
Are any of these going to be the next big thing?